Christophe Arbet-Engels

Christophe brings more than 25 years of experience in life sciences, academia, biotech & large pharmaceutical industry and, more recently, as Chief Medical Officer at Millendo Therapeutics and Poxel Pharmaceuticals, with responsibility for all medical activities, including driving portfolio strategy and execution of US and global registration programs. Prior to joining Millendo Therapeutics, he led and contributed to several pre-IND to late-stage development programs in Cardiometabolic, Oncology, Neurology, Hematology and Rare Diseases and he launched several therapies as global or US head of Clinical Development and Medical Affairs, including blockbusters Lantus and Jardiance and, recently, Twymeeg in Japan. Christophe has a M.D. and a Ph.D. in internal medicine/endocrinology-metabolism from the University of Paris, France and an MBA in finance from Rutgers University, NJ.